Telomir Pharmaceuticals, Inc. Basic Shares Outstanding (Weighted Average)
Telomir Pharmaceuticals, Inc. (TELO) reported Basic Shares Outstanding (Weighted Average) of 60.84 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 60.84M shares, a 102.72% increase year-over-year.
- Telomir Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 34.38M shares, a 15.52% increase year-over-year.
- Telomir Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 33.49M shares, a 12.92% increase year-over-year.
- Telomir Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 32.40M shares, a 9.42% increase year-over-year.
- Telomir Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 31.65M shares, a 7.16% increase from fiscal 2024.
- Telomir Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 29.54M shares, a 8.18% increase from fiscal 2023.
- Telomir Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 27.30M shares, a 1.77% increase from fiscal 2022.
- Telomir Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 26.83M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 60.84M shares 10-Q · filed 2026-08-13 | 47.68M shares 10-Q · filed 2026-08-13 | 42.90M shares derived: average of 3 quarters · filed 2026-08-13 | 40.28M shares derived: average of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | 34.38M shares 10-Q · filed 2026-05-14 | 33.94M shares derived: average of 2 quarters · filed 2026-05-14 | 33.42M shares derived: average of 3 quarters · filed 2026-05-14 | 32.57M shares derived: average of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | 33.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 32.95M shares derived: average of 2 quarters · filed 2026-03-17 | 31.97M shares derived: average of 3 quarters · filed 2026-08-13 | 31.65M shares 10-K · filed 2026-03-17 | |
| 2025-09-30 | 32.40M shares 10-Q · filed 2025-11-10 | 31.20M shares derived: average of 2 quarters · filed 2026-08-13 | 31.04M shares 10-Q · filed 2025-11-10 | 30.46M shares derived: average of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | 30.01M shares 10-Q · filed 2026-08-13 | 30.27M shares 10-Q · filed 2026-08-13 | 29.81M shares derived: average of 3 quarters · filed 2026-08-13 | 29.76M shares derived: average of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | 29.76M shares 10-Q · filed 2026-05-14 | 29.71M shares derived: average of 2 quarters · filed 2026-05-14 | 29.68M shares derived: average of 3 quarters · filed 2026-05-14 | 29.66M shares derived: average of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | 29.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 29.64M shares derived: average of 2 quarters · filed 2026-03-17 | 29.63M shares derived: average of 3 quarters · filed 2026-03-17 | 29.54M shares 10-K · filed 2026-03-17 | |
| 2024-09-30 | 29.61M shares 10-Q · filed 2025-11-10 | 29.61M shares derived: average of 2 quarters · filed 2025-11-10 | 29.50M shares 10-Q · filed 2025-11-10 | 28.90M shares derived: average of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | 29.61M shares 10-Q · filed 2025-08-14 | 29.44M shares 10-Q · filed 2025-08-14 | 28.66M shares derived: average of 3 quarters · filed 2025-08-14 | 28.27M shares derived: average of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | 29.28M shares 10-Q · filed 2025-05-14 | 27.77M shares 10-Q · filed 2024-05-13 | 28.19M shares derived: average of 2 quarters · filed 2025-05-14 | 27.82M shares derived: average of 3 quarters · filed 2025-05-14 | 27.64M shares derived: average of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | 27.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | 27.10M shares derived: average of 2 quarters · filed 2025-02-04 | 27.10M shares derived: average of 3 quarters · filed 2025-02-04 | 27.30M shares 10-K · filed 2025-02-04 | |
| 2023-09-30 | 27.10M shares 10-Q · filed 2024-11-12 | 27.10M shares derived: average of 2 quarters · filed 2024-11-12 | 27.37M shares 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 27.10M shares 10-Q · filed 2024-08-13 | 27.02M shares 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 26.89M shares 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | 26.83M shares 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |